Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics, Inc. - Common Stock
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karuna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
↗
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
August 09, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
8 Analysts Have This to Say About Karuna Therapeutics
↗
August 09, 2022
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:
Via
Benzinga
Karuna Therapeutics: Q2 Earnings Insights
↗
August 08, 2022
Karuna Therapeutics (NASDAQ:KRTX) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
SVB Likes This 'Novel Antipsychotic'-Focused Stock
↗
July 14, 2022
Via
Benzinga
JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock
↗
June 28, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
↗
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
↗
August 09, 2022
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Via
Benzinga
GameStop, Signify Health And Some Other Big Gainers From Monday
↗
August 09, 2022
U.S. stocks closed mixed on Monday. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Analyst Ratings for Karuna Therapeutics
↗
June 28, 2022
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:
Via
Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
↗
August 09, 2022
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
Via
Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
↗
August 08, 2022
Via
Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Nasdaq Turns Lower; Crude Oil Rises Over 1%
↗
August 08, 2022
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
August 08, 2022
Via
Benzinga
Karuna Therapeutics (NASDAQ: KRTX) Reports Positive Primary and Secondary Endpoint Results from Phase 3 EMERGENT-2 Clinical Trial of KarXT for Treating Schizophrenia
August 08, 2022
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is engaged as a clinical-stage biopharmaceutical company that is focused on the research and development
Via
Spotlight Growth
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
August 08, 2022
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6...
Via
Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data
↗
August 08, 2022
Karuna Therapeutics (KRTX) stock is rocketing higher on Monday thanks to results from a Phase 3 EMERGENT-2 trial to treat schizophrenia.
Via
InvestorPlace
Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win
↗
August 08, 2022
Karuna Therapeutics easily beat expectations for its midstage test in schizophrenia.
Via
Investor's Business Daily
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
↗
August 08, 2022
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday.
Via
Benzinga
Karuna Therapeutics Shares Surge After Encouraging Data From Schizophrenia Candidate
↗
August 08, 2022
Karuna Therapeutics Inc (NASDAQ: KRTX) has
Via
Benzinga
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
August 04, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022
↗
July 14, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
↗
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
June 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
↗
May 26, 2022
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
